EA033046B1 - Состав, содержащий пролекарство гемцитабина - Google Patents
Состав, содержащий пролекарство гемцитабинаInfo
- Publication number
- EA033046B1 EA033046B1 EA201692422A EA201692422A EA033046B1 EA 033046 B1 EA033046 B1 EA 033046B1 EA 201692422 A EA201692422 A EA 201692422A EA 201692422 A EA201692422 A EA 201692422A EA 033046 B1 EA033046 B1 EA 033046B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formulations
- gemcitabine
- relates
- alaninyl
- benzoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к фармацевтическим составам гемцитабин[фенил(бензокси-L-аланинил)]фосфата, монофосфатного производного хорошо известного противоопухолевого лекарственного средства гемцитабина. В частности, изобретение относится к составам, которые содержат полярный апротонный растворитель, предпочтительно диметилацетамид (ДМА). Составы, содержащие указанный растворитель, оказывают терапевтически эффективное лечение гемцитабин[фенил(бензокси-L-аланинил)]фосфатом. Изобретение также относится к способам применения указанных составов и наборов, содержащих указанные составы.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2050MU2014 | 2014-06-25 | ||
GBGB1411253.6A GB201411253D0 (en) | 2014-06-25 | 2014-06-25 | Prodrug |
GBGB1417646.5A GB201417646D0 (en) | 2014-10-06 | 2014-10-06 | Formulations of phosphate derivatives |
PCT/GB2015/051858 WO2015198059A1 (en) | 2014-06-25 | 2015-06-25 | Formulation comprising a gemcitabine-prodrug |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201692422A1 EA201692422A1 (ru) | 2017-04-28 |
EA033046B1 true EA033046B1 (ru) | 2019-08-30 |
Family
ID=53499028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692422A EA033046B1 (ru) | 2014-06-25 | 2015-06-25 | Состав, содержащий пролекарство гемцитабина |
Country Status (29)
Country | Link |
---|---|
US (4) | US10117888B2 (ru) |
EP (2) | EP3119794B1 (ru) |
JP (3) | JP6855248B2 (ru) |
KR (2) | KR20220104270A (ru) |
CN (2) | CN106470672B (ru) |
AU (2) | AU2015278900B2 (ru) |
BR (1) | BR112016025787B1 (ru) |
CA (1) | CA2944966C (ru) |
CL (1) | CL2016003261A1 (ru) |
CY (1) | CY1119772T1 (ru) |
DK (1) | DK3119794T3 (ru) |
EA (1) | EA033046B1 (ru) |
ES (1) | ES2655820T3 (ru) |
HK (1) | HK1244437A1 (ru) |
HR (1) | HRP20180007T1 (ru) |
HU (1) | HUE036011T2 (ru) |
IL (2) | IL248345B (ru) |
LT (1) | LT3119794T (ru) |
MX (2) | MX2020004054A (ru) |
MY (1) | MY186584A (ru) |
NO (1) | NO3119794T3 (ru) |
PH (1) | PH12016502552A1 (ru) |
PL (1) | PL3119794T3 (ru) |
PT (1) | PT3119794T (ru) |
RS (1) | RS56752B1 (ru) |
SG (1) | SG11201608809RA (ru) |
SI (1) | SI3119794T1 (ru) |
TW (2) | TWI674097B (ru) |
WO (1) | WO2015198059A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
PL3447061T3 (pl) | 2011-03-01 | 2022-01-31 | NuCana plc | Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu |
RS58849B1 (sr) | 2012-11-16 | 2019-07-31 | Univ College Cardiff Consultants Ltd | Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata |
WO2015198058A1 (en) * | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Gemcitabine prodrugs |
CN106470672B (zh) * | 2014-06-25 | 2019-11-05 | 努卡那生物医药有限责任公司 | 包括吉西他滨前药的制剂 |
GB201417644D0 (en) * | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
KR20230098915A (ko) | 2014-11-28 | 2023-07-04 | 뉴카나 피엘씨 | 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체 |
CN106543252A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药(苏州)股份有限公司 | 核苷氨基磷酸酯类前药的制备方法及其中间体 |
CN106543220A (zh) | 2015-09-16 | 2017-03-29 | 博瑞生物医药(苏州)股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
CN106539810B (zh) * | 2015-09-16 | 2021-03-09 | 济南高合医疗科技有限公司 | 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途 |
MX2018004137A (es) | 2015-10-05 | 2018-06-13 | NuCana plc | Terapia de combinacion. |
EP4011896A1 (en) | 2015-12-11 | 2022-06-15 | NuCana plc | Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031 |
GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
CA3041121A1 (en) | 2016-11-02 | 2018-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
MX2020000488A (es) | 2017-07-20 | 2020-10-28 | Centrexion Therapeutics Corp | Metodos y composiciones para el tratamiento del dolor usando capsaicina. |
GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
CN109956986B (zh) | 2017-12-22 | 2021-04-27 | 浙江柏拉阿图医药科技有限公司 | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 |
WO2023076878A1 (en) * | 2021-10-26 | 2023-05-04 | Emphascience Inc. | Ready-to-dilute formulation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008087488A2 (en) * | 2006-10-22 | 2008-07-24 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2317505C (en) | 1998-01-23 | 2011-01-04 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
DE60042073D1 (de) | 1999-07-22 | 2009-06-04 | Celmed Oncology Usa Inc | Enzym katalisierte therapeutische aktivierung |
CN1181829C (zh) * | 2000-11-03 | 2004-12-29 | 中国人民解放军军事医学科学院附属医院 | 吉西他滨溶液制剂 |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
WO2006081364A2 (en) | 2005-01-27 | 2006-08-03 | Erimos Pharmaceuticals Llc | Formulations for injection of catecholic butanes, including ndga compounds, into animals |
US8492400B2 (en) * | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
WO2011008985A2 (en) * | 2009-07-15 | 2011-01-20 | Georgia Tech Research Corporation | Methods and compositions for improved delivery of therapeutic and diagnostic agents |
MX2012005677A (es) * | 2009-11-20 | 2012-08-23 | Clavis Pharma Asa | Formulaciones parentales de derivados de gemcitabina. |
CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
KR101231925B1 (ko) * | 2010-10-27 | 2013-02-08 | 씨제이제일제당 (주) | 젬시타빈의 전구약물 및 이의 제조방법 |
EP2804582B1 (en) * | 2012-01-20 | 2016-03-30 | Aratana Therapeutics NV | Eye drop composition |
CA2890359A1 (en) * | 2012-11-07 | 2014-05-15 | Zucai SUO | Substituted gemcitabine aryl amide analogs and treatment methods using same |
RS58849B1 (sr) | 2012-11-16 | 2019-07-31 | Univ College Cardiff Consultants Ltd | Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata |
JP2017504572A (ja) | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
WO2015198058A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Gemcitabine prodrugs |
CN106470672B (zh) | 2014-06-25 | 2019-11-05 | 努卡那生物医药有限责任公司 | 包括吉西他滨前药的制剂 |
JP6646663B2 (ja) | 2014-07-22 | 2020-02-14 | ニューカナ バイオメッド リミテッドNucana Biomed Limited | ゲムシタビン−[フェニル(ベンゾキシ−l−アラニニル)]ホスフェートの製造方法リン酸誘導体を製造する方法 |
GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
EP3197456B2 (en) | 2015-05-14 | 2023-10-11 | NuCana plc | Cancer treatments |
MX2018004137A (es) | 2015-10-05 | 2018-06-13 | NuCana plc | Terapia de combinacion. |
EP4011896A1 (en) | 2015-12-11 | 2022-06-15 | NuCana plc | Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031 |
WO2017109444A1 (en) | 2015-12-23 | 2017-06-29 | Nucana Biomed Limited | Combination therapy |
WO2017109486A1 (en) | 2015-12-23 | 2017-06-29 | Nucana Biomed Limited | Combination therapy |
GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2015
- 2015-06-25 CN CN201580034742.9A patent/CN106470672B/zh active Active
- 2015-06-25 NO NO15733498A patent/NO3119794T3/no unknown
- 2015-06-25 MX MX2020004054A patent/MX2020004054A/es unknown
- 2015-06-25 RS RS20180003A patent/RS56752B1/sr unknown
- 2015-06-25 WO PCT/GB2015/051858 patent/WO2015198059A1/en active Application Filing
- 2015-06-25 DK DK15733498.8T patent/DK3119794T3/en active
- 2015-06-25 EP EP15733498.8A patent/EP3119794B1/en active Active
- 2015-06-25 TW TW104120487A patent/TWI674097B/zh active
- 2015-06-25 CA CA2944966A patent/CA2944966C/en active Active
- 2015-06-25 ES ES15733498.8T patent/ES2655820T3/es active Active
- 2015-06-25 MY MYPI2016002149A patent/MY186584A/en unknown
- 2015-06-25 AU AU2015278900A patent/AU2015278900B2/en active Active
- 2015-06-25 CN CN201911065790.0A patent/CN110882268A/zh active Pending
- 2015-06-25 US US15/308,475 patent/US10117888B2/en active Active
- 2015-06-25 EA EA201692422A patent/EA033046B1/ru unknown
- 2015-06-25 KR KR1020227023672A patent/KR20220104270A/ko not_active Application Discontinuation
- 2015-06-25 BR BR112016025787-1A patent/BR112016025787B1/pt active IP Right Grant
- 2015-06-25 TW TW108132019A patent/TWI765176B/zh active
- 2015-06-25 HU HUE15733498A patent/HUE036011T2/hu unknown
- 2015-06-25 PT PT157334988T patent/PT3119794T/pt unknown
- 2015-06-25 PL PL15733498T patent/PL3119794T3/pl unknown
- 2015-06-25 EP EP17189351.4A patent/EP3269391A1/en active Pending
- 2015-06-25 SG SG11201608809RA patent/SG11201608809RA/en unknown
- 2015-06-25 MX MX2016015629A patent/MX2016015629A/es active IP Right Grant
- 2015-06-25 KR KR1020167033376A patent/KR102421929B1/ko active IP Right Grant
- 2015-06-25 SI SI201530157T patent/SI3119794T1/en unknown
- 2015-06-25 LT LTEP15733498.8T patent/LT3119794T/lt unknown
- 2015-06-25 JP JP2016574458A patent/JP6855248B2/ja active Active
-
2016
- 2016-10-13 IL IL248345A patent/IL248345B/en active IP Right Grant
- 2016-12-20 CL CL2016003261A patent/CL2016003261A1/es unknown
- 2016-12-20 PH PH12016502552A patent/PH12016502552A1/en unknown
-
2017
- 2017-02-04 HK HK18103928.1A patent/HK1244437A1/zh unknown
-
2018
- 2018-01-03 HR HRP20180007TT patent/HRP20180007T1/hr unknown
- 2018-01-11 CY CY20181100037T patent/CY1119772T1/el unknown
- 2018-09-26 US US16/142,948 patent/US10786523B2/en active Active
-
2019
- 2019-06-27 AU AU2019204557A patent/AU2019204557B2/en active Active
-
2020
- 2020-01-29 JP JP2020012388A patent/JP6970221B2/ja active Active
- 2020-07-21 IL IL276199A patent/IL276199B/en unknown
- 2020-09-02 US US17/010,338 patent/US11040051B2/en active Active
-
2021
- 2021-05-19 US US17/324,835 patent/US11707477B2/en active Active
- 2021-10-28 JP JP2021176770A patent/JP7329025B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008087488A2 (en) * | 2006-10-22 | 2008-07-24 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
Non-Patent Citations (2)
Title |
---|
Bilir A., Guneri A.D., Altinoz M.A.: "Acetaminophen and DMSO modulate growth and gemcitabine cytotoxicity in FM3A breast cancer cells in vitro", NEOPLASMA, vol. 51, no. 6, 1 January 2004 (2004-01-01), 2004, pages 460-464, XP055205686, Retrieved from the Internet: URL:http://www.elis.sk/download_file.php?product_id=704&session_idd4h527oor14r6t55q2codkfqq1 [retrieved on 2015-07-31], abstract, page 463, right-hand column, lines 24-26 * |
MAGDALENA SLUSARCZYK, MONICA HUERTA LOPEZ, JAN BALZARINI, MALCOLM MASON, WEN G. JIANG, SARAH BLAGDEN, EMELY THOMPSON, ESSAM GHAZAL: "Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 57, no. 4, 27 February 2014 (2014-02-27), pages 1531 - 1542, XP055205033, ISSN: 00222623, DOI: 10.1021/jm401853a * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA033046B1 (ru) | Состав, содержащий пролекарство гемцитабина | |
MX2023010042A (es) | Polinucleotidos moduladores. | |
MX2023008693A (es) | Polinucleotidos moduladores. | |
WO2017095944A8 (en) | Methods and compositions relating to chondrisomes from blood products | |
EP3313404A4 (en) | THERAPEUTIC COMPOSITIONS, ASSOCIATIONS AND METHODS OF USE | |
EP3389725A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
EP3349762A4 (en) | CO-CRYSTALS OF SGLT2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
MX2021006734A (es) | Metodo para tratar el cancer. | |
EP3307754A4 (en) | NICOTINAMIDRIBOSIDE AND PTEROSTODY COMPOSITIONS AND METHOD FOR TREATING SKIN DISEASES | |
MX2020004454A (es) | Manufactura de productos de interpolimero de etileno a una mayor tasa de produccion. | |
EP3487537A4 (en) | ZWITTERONIC MICROGELS, THEIR ASSEMBLIES AND ASSOCIATED FORMULATIONS, AND METHODS OF USE | |
PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
EP3349599A4 (en) | INHIBITABLE NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF | |
EP3380525A4 (en) | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE | |
GB201522764D0 (en) | Formulations of phosphate derivatives | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
EP3471738A4 (en) | PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | |
EP3244900A4 (en) | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | |
EP3313520A4 (en) | Therapeutic uses of berberine formulations | |
MX2016004078A (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
EP3325019A4 (en) | COMPOSITES AND COMPOSITIONS FOR USE IN THERAPEUTIC PURPOSE AND METHODS OF MAKING AND USING SAME | |
EP3506947A4 (en) | PHARMACEUTICAL FORMULATIONS OF REGADENOSONE | |
EP3471739A4 (en) | USE OF PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | |
EP3471737A4 (en) | CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE COMPOUND AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES |